GlassScriptPhysician profile
Kevin Fluckiger
NPI 1083117584
$2,571.82
in general payments reported to CMS, 2019-2025
22 companies · $49.82 in 2025
The $49.82 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2022: $324 · 2023: $59.35 · 2024: $1,157 · 2025: $49.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $829 · Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $829.09 |
| Food and Beverage | $437.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Active Medical, LLC | $918.00 | 2019 | |
| Arthrex, INC. | $600.30 | 2024 | |
| Tricoast Surgical Solutions LLC | $472.76 | 2024 | |
| Medtronic, INC. | $84.33 | 2024 | Intellis Adaptivestim |
| Lilly USA, LLC | $72.36 | 2022 | |
| Paragon 28, INC. | $62.83 | 2019 | |
| Alexion Pharmaceuticals, INC. | $45.92 | 2022 | |
| Xeris Pharmaceuticals, INC. | $41.46 | 2022-2023 | Gvoke Hypopen |
| Paratek Pharmaceuticals, INC. | $35.42 | 2025 | Nuzyra |
| Amryt Pharma Holdings LTD | $24.61 | 2022 | |
| Eusa Pharma (US) LLC | $21.14 | 2022 | |
| Recordati_rare_diseases_inc. | $21.14 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.64 | 2022 | |
| Tandem Diabetes Care, INC. | $20.43 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $20.07 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $18.49 | 2023 | 3m Coban, Activ.A.C. |
| Bayer Healthcare Pharmaceuticals INC. | $18.15 | 2022 | |
| Dexcom, INC. | $18.09 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.76 | 2022 | |
| Treace Medical Concepts, INC. | $14.66 | 2022 | |
| Madrigal Pharmaceuticals | $14.40 | 2025 | Rezdiffra |
| Grt US Holding, INC. | $10.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Fluckiger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.